- CONDITION CENTERS
Methylphenidate Hydrochloride Extended-release Capsules (la)
Marketed by: Actavis (Morristown, NJ)
Compared to: Ritalin (Novartis)
Indication: The FDA approved methylphenidate hydrochloride extended-release capsules (LA), a central nervous system stimulant, for the treatment of attention-deficit/hyperactivity disorder. Actavis has first-to-file exclusivity on the 20-, 30-, and 40-mg strengths. Methylphenidate hydrochloride extended-release capsules (LA) are administered orally once daily in the morning. Alternately, the capsule contents may be sprinkled on a small amount of applesauce and immediately consumed. Methylphenidate hydrochloride extended-release capsules (LA) should not be administered to children younger than 6 years, as safety and efficacy in this age group has not been established.
Dosage Form: Capsules: 20, 30, and 40 mg
For More Information: www.actavis.us
Marketed by: Sancilio & Company, Inc (Riviera Beach, FL)
Indication: Sancilio & Company, Inc announced the release of PréNata, a generic prenatal multivitamin indicated to provide vitamin and mineral supplementation throughout pregnancy and during the postnatal period for both lactating and nonlactating mothers. The fruit-flavored tablets are also useful for improving nutritional status prior to conception. The recommended dosage is 1 tablet daily with a meal. The chewable formulation provides an alternative to patients who experience nausea from large or difficult-to-swallow tablets. Patients can also crush PréNata tablets to take with food or swallow with water without affecting their nutritional value.
Dosage Form: Chewable tablets in 90-count bottles
For More Information: www.sancilio.com
Clobetasol Propionate Shampoo, 0.05%
Marketed by: Sandoz (Princeton, NJ)
Compared to: Clobex Shampoo, 0.05% (Galderma Laboratories)
Indication: Sandoz announced the availability of their authorized generic clobetasol propionate shampoo, 0.05%, in the United States. Clobetasol propionate shampoo, 0.05%, is a topical corticosteroid indicated for the treatment of moderate to severe forms of scalp psoriasis in patients 18 years and older. Treatment with clobetasol propionate shampoo, 0.05%, should be limited to 4 weeks because of its potential to suppress the hypothalamic-pituitary-adrenal axis. The total dosage should not exceed 50 g (50 mL or 1.75 fl oz) per week.
Dosage Form: Shampoo: supplied in 4–fl oz bottles
For More Information: www.us.sandoz.com
Lamivudine and Zidovudine Tablets USP
Marketed by: Teva Pharmaceuticals (North Wales, PA)
Compared to: Combivir Tablets (ViiV Healthcare)
Indication: Teva Pharmaceuticals announced the introduction and availability of lamivudine and zidovudine tablets USP, which are AB rated and bioequivalent to Combivir Tablets. Lamivudine and zidovudine tablets are a combination of 2 nucleoside analogue reverse transcriptase inhibitors indicated for the treatment of HIV-1 infection. The dosage for adults and adolescents weighing 30 kg or more is 1 tablet twice daily. Pediatric dosing should be based on body weight and should not exceed adult dosing. This fixed-dose product should not be used in pediatric patients weighing less than 30 kg, or in patients requiring dose adjustment.
Dosage Form: Tablets: 150/300 mg lamivudine/zidovudine
For More Information: www.tevausa.com